Akash Mourya | Health and Medicine Advances | Best Researcher Award

Published on by New Scientists

Mr. Akash Mourya | Health and Medicine Advances | Best Researcher Award

PhD Scholar | National Institutes of Pharmaceutical Education and Research | India

Mr. Akash Mourya is a promising young pharmacologist specializing in pharmacology and toxicology, with a strong research focus on liver pathophysiology, hepatoprotective drug discovery, and molecular mechanisms underlying hepatic and pulmonary disorders. His ongoing Ph.D. work at NIPER Mohali builds on extensive preclinical and translational research conducted at the Institute of Liver and Biliary Sciences (ILBS), New Delhi, where he has developed expertise in animal models of liver diseases, hemodynamic studies, and hepatic cell culture systems. His research contributions have advanced understanding of non-alcoholic and alcoholic fatty liver diseases, hepatopulmonary and porto-pulmonary hypertension, and liver regeneration mechanisms. He has co-authored seven peer-reviewed publications in high-impact journals, including Journal of Hepatology, JHEP Reports, American Journal of Physiology–Gastrointestinal and Liver Physiology, npj Gut and Liver, ACS Omega, and Life Sciences. His work has collectively received 31 citations, 7 Documents, with an h-index of 3, reflecting growing recognition within the biomedical research community. In addition to journal articles, Mr. Akash Mourya has contributed two book chapters published by Springer Nature (2024) and Academic Press (2025), covering topics such as oxidative stress and pharmacological interventions in liver disease, and PPARγ signaling in diabetes. His research abstracts have been presented at prestigious international conferences, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL). His work integrates pharmacological innovation, molecular biology, and experimental therapeutics, with emphasis on Ayurvedic formulations, CB2 receptor agonists, and novel siRNA nanoparticle delivery systems. Mr. Akash Mourya’s ongoing efforts contribute to translational R&D for liver protection and regeneration, aligning with India’s growing emphasis on integrative pharmacology and precision medicine.

Profiles: Scopus | Google Scholar | ResearchGate | PubMed 

Featured Publications

1. Baweja, S., Kumari, A., Negi, P., Tomar, A., Tripathi, D. M., Mourya, A. K., Rastogi, A., Subudhi, P. D., Thangariyal, S., Kumar, G., Kumar, J., Sood, A., Vashistha, C., Bihari, C., Maiwall, R., & Sarin, S. K. (2023). Hepatopulmonary syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod. Journal of Hepatology, 79(1), 167–180.

2. Juneja, P., Rahman, S. N. R., Jakhar, D., Mourya, A. K., Tripathi, D. M., Kaur, I., Tiwari, V., & others. (2023). Recombinant VEGF-C (Cys156Ser) improves mesenteric lymphatic drainage and gut immune surveillance in experimental cirrhosis. JHEP Reports, 5(10), 100816.

3. Biswas, S., Yadav, N., Juneja, P., Mourya, A. K., Kaur, S., Tripathi, D. M., & Chauhan, V. S. (2022). Conformationally restricted dipeptide-based nanoparticles for delivery of siRNA in experimental liver cirrhosis. ACS Omega, 7(41), 36811–36824.

4. Kaur, I., Juneja, P., Tiwari, R., Vasudevan, A., Mourya, A. K., Trauner, M., Sarin, S. K., & Tripathi, D. M. (2024). Secondary bile acids in portal blood contribute to liver regeneration in a rat model of partial hepatectomy. American Journal of Physiology – Gastrointestinal and Liver Physiology, 327(4), G645–G658.

5. Tripathi, D. M., Singh, P., Mourya, A. K., & Kaur, S. (2024). Oxidative medicine and novel pharmacological treatment approaches in liver disease. In Adaptation under stressful environments through biological adjustments and interventions (pp. 311–334). Springer Nature.

 

Bing Han | Health and Medicine Advances | Best Researcher Award

Published on by New Scientists

Dr. Bing Han | Health and Medicine Advances | Best Researcher Award

Postdoctoral Researcher, The First Affiliated Hospital of Zhengzhou University, China

Dr. Bing Han, Professor at The First Affiliated Hospital of Zhengzhou University, China, is an accomplished medical scientist and clinician whose research bridges molecular biology, microbiome science and clinical gastroenterology. He earned his medical degree (M.D.) followed by postdoctoral research training focused on digestive disease mechanisms and microbial interactions, establishing a strong foundation in translational and precision medicine. His primary research interests center on the gut microbiota–host interaction, bile acid metabolism, intestinal inflammation and biomarker discovery for digestive disorders, with emerging interests in microbiome-based therapeutic interventions. Over his distinguished career, Dr. Bing Han has held academic and clinical roles at The First Affiliated Hospital of Zhengzhou University and collaborated with The First Affiliated Hospital of the University of Science and Technology of China, contributing to interdisciplinary advancements in medical research. His key scientific contributions include innovative studies on the mechanisms of fecal microbiota transplantation in improving inflammatory bowel disease (IBD) and the development of biomedical devices such as spinal positioning systems and femoral defect fixation stents. He has published 9 scientific documents, receiving 50 citations with an h-index of 5 and authored the academic book Frontiers of Tumor Research. Among his notable research supports are the China Postdoctoral Science Foundation Grant, National Natural Science Foundation of China Grant and the Guangxi Natural Science Foundation and Health Commission Projects of Guangxi Zhuang Autonomous Region. His professional engagements include serving as a Young Editorial Board Member for the Journal of Guangxi Medical University and membership in the Digestive Professional Committee of the Chinese Society of Pathophysiology and the Gut Microbiota Branch of the Chinese Society of Biophysics. Through his pioneering research on gut microbiota and digestive pathophysiology, Dr. Bing Han aims to revolutionize clinical diagnostics and therapeutics, promoting global health advancement and innovation in biomedical science.

Profile: Scopus | ORCID | ResearchGate

Featured Publications

1. Han, B., Tang, D., Zhu, H., et al. (2024). Integrated multi-omics reveal gut microbiota-mediated bile acid metabolism regulating immunotherapy responses to anti-α4β7-integrin in Crohn’s disease. Gut Microbes, 16(1), 2310894.

2. Han, B., Li, C., Meng, H., et al. (2019). Efficacy and safety of external-beam radiation therapy for hepatocellular carcinoma: An overview of current evidence according to the different target population. Bioscience Trends, 13(1), 10–22.

3. Han, B., Tang, D., Lv, X., et al. (2023). Comparative efficacy and safety of combination therapy with infliximab for Crohn’s disease: A systematic review and network meta-analysis. International Journal of Colorectal Disease, 38(1), 82.

4. Han, B., Shao, L., Li, C., et al. (2019). Surgery versus external beam radiation therapy for AJCC stage I hepatocellular carcinoma. Journal of BUON, 24(4), 1390–1401.

5. Han, B., Yao, H., Shao, L., et al. (2018). Selection of treatment modalities for hepatocellular carcinoma at stages T1 and T2: A preliminary analysis based on the Surveillance, Epidemiology, and End Results registry database. Journal of BUON, 23(3), 611–621.

 

Seema Kandalkar | Health and Medicine Advances | Best Researcher Award

Published on by New Scientists

Ms. Seema Kandalkar | Health and Medicine Advances | Best Researcher Award

Student, Sanjivani College of Pharmaceutical Education and Research, Kopargaon (SPPU), India

Ms. Seema Kandalkar is a dedicated pharmaceutical researcher currently serving as an IPR Trainee at Trexo Global Pvt. Ltd, Nashik, and is affiliated with Sanjivani College of Pharmaceutical Education and Research (SPPU). She completed her M. Pharmacy in Pharmaceutics from Sanjivani College of Pharmaceutical Education and Research, Kopargaon, in 2025, following a B. Pharmacy from Pravara Rural Education Society College of Pharmacy (SPPU, 2023). Her research primarily focuses on formulation and development of innovative drug delivery systems, including probiotic and effervescent tablet formulations, with emerging interests in regulatory affairs and intellectual property rights. She has gained significant hands-on experience through her industrial projects and internships at Sci-Tech Efferceuticals (R&D), Sanpras Healthcare Pvt. Ltd., and Reve Pharma, where she honed practical skills in analytical techniques, GMP, stability studies, dissolution testing and drug delivery design. Among her key contributions, she successfully developed and evaluated a probiotic effervescent tablet during her M. Pharmacy project and has disseminated her findings via a review article accepted in Journal of Future Foods (ScienceDirect, IF 7.2), along with poster presentations at international conferences and participation in national-level research competitions. Her work has been recognized for its academic rigor and innovative approach in pharmaceutical sciences, earning accolades through national seminars and competitive workshops. Professionally, she is skilled in Microsoft Office Suite, BioRender and Zotero and actively participates in scientific workshops and seminars. Author metrics for Ms. Seema Kandalkar include 1 published document with citation potential, currently reflecting initial scholarly impact. Her work contributes to advancing formulation science, promoting effective healthcare solutions, and strengthening pharmaceutical innovation and intellectual property awareness. Her vision encompasses enhancing patient-centric drug delivery, fostering regulatory excellence and contributing to global pharmaceutical research standards. With her blend of academic excellence, industrial exposure and research innovation, Ms. Seema Kandalkar is well-positioned to make significant contributions to pharmaceutical sciences and healthcare innovation internationally.

Profile: ORCID | ResearchGate | LinkedIn

Featured Publications

1. Kandalkar, S. T., Shendge, R. S., & Lohakare, O. K. (2025). Unveiling the therapeutic potential of probiotics: A review. Journal of Future Foods. Advance online publication.

 

Jie Wu | Health and Medicine | Best Researcher Award

Published on by New Scientists

Prof. Dr. Jie Wu | Health and Medicine | Best Researcher Award

Professor and Lab Director, Shantou University Medical College, China

Prof. Dr. Jie Wu is a Distinguished Professor and Director of the Laboratory of Brain Function and Disease at Shantou University Medical College, China, and formerly served as Professor and Director of the Neurophysiology Laboratory at the Barrow Neurological Institute (BNI), St. Joseph’s Hospital and Medical Center, USA. He earned his M.D. from Xuzhou Medical College in 1983 and Ph.D. in Neurophysiology from Sun Yat-sen University of Medical Sciences in 1990, followed by postdoctoral fellowships at Tohoku University School of Medicine, Japan (1993–1994), and the University of New Mexico, USA (1994–1997). His research focuses on the physiology and pharmacology of nicotinic acetylcholine receptors (nAChRs), molecular mechanisms of epilepsy, and neurodegenerative disorders related to amyloid beta (Aβ) and receptor dysfunction, as well as ATP-sensitive potassium (KATP) channel regulation. Over three decades, he has led groundbreaking neuroscience research funded by the U.S. National Institutes of Health (NIH), the State of Arizona, and various international foundations, making fundamental discoveries in synaptic receptor signaling and neurodegeneration. His pioneering contributions have led to nearly 200 peer-reviewed publications, five book chapters, and eight patents (four U.S. and four Chinese), providing novel insights into receptor-mediated neurological diseases and translational therapies. Among his many honors, Prof. Dr. Jie Wu has received the China National Natural Science Award and the International HH Rosenfield Rekate Pioneer Award, and was listed among the World’s Top 2% Scientists (2022) and elected as a Fellow of the Royal Society of Arts (FRSA, UK, 2024). He serves as Editor-in-Chief and editorial board member for leading international journals and is active in global neuroscience and biomedical societies. With 161 documents, 5,887 citations and an h-index of 44, Prof. Dr. Jie Wu exemplifies research excellence and leadership, advancing global neuroscience through innovation, collaboration, and mentorship that continues to shape the future of brain science and human health worldwide.

Profile: Scopus | ORCID | Google Scholar | ResearchGate | Sci Profiles | Loop | LONGDOM | LinkedIn 

Featured Publications

1. Zhang, X. X., Gao, M., Liu, Q. R., Bi, G. H., Li, X., Yang, H. J., Gardner, E. L., & Wu, J. (2014). Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proceedings of the National Academy of Sciences of the United States of America, 111(46), E5007–E5015.

2. Liu, Q., Huang, Y., Xue, F., Simard, A., DeChon, J., Li, G., Zhang, J., Lucero, L., & Wu, J. (2009). A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. Journal of Neuroscience, 29(4), 918–929.

3. Wang, T. N., Yang, W., Wang, Y., Nagaraj, V. J., Liu, Q., & Wu, J. (2012). Label-free measuring and mapping of binding kinetics of membrane proteins in single living cells. Nature Chemistry, 4(10), 846–853.

4. Chen, D. J., Gao, M., Gao, F. F., Su, Q. X., & Wu, J. (2017). Brain cannabinoid receptor 2: Expression, function and modulation. Acta Pharmacologica Sinica, 38(3), 312–316.

5. Okada, Y. C., Wu, J., & Kyuhou, S. (1997). Genesis of MEG signals in a mammalian CNS structure. Electroencephalography and Clinical Neurophysiology, 103(4), 474–485.

 

Priyanka Garg | Health and Medicine | Best Researcher Award

Published on by New Scientists

Ms. Priyanka Garg | Health and Medicine | Best Researcher Award

Assistant Professor, Lovely Professional University, India

Ms. Priyanka Garg is currently serving as an Assistant Professor at the School of Pharmaceutical Sciences, Lovely Professional University (LPU), Punjab, India, where she contributes actively to academic instruction, clinical research, and student mentorship. She holds an M.Pharm in Pharmacy Practice (2022) and a B.Pharm (2020), both from Lovely Professional University, with specialization in pharmacotherapy, pharmacovigilance, and patient-centered care. Her primary research interests encompass pharmacogenomics, clinical pharmacology, women’s health, chronic disease management, and the role of gut microbiota in metabolic disorders, with emerging work focusing on personalized medicine for PCOS and Ehlers-Danlos Syndrome. Professionally, she has served at LPU since January 2023 and previously trained at Shiva Biogenetic Pharmaceuticals Pvt. Ltd. and Doaba Hospital Pvt. Ltd., where she gained practical expertise in manufacturing, IPQC, patient monitoring, and clinical data analysis. Her key contributions include two granted copyrights—“Laboratory and Clinical Result for Polycystic Ovary Syndrome” (2024) and “Clinical Findings for Ehlers-Danlos Syndrome” (2025)—and several impactful presentations at national and international conferences such as SHE-SCIENCE 2025 and the International Conference of Pharmacy series. She has published indexed research in reputed journals including Obesity Medicine and Human Gene. Her scholarly influence is reflected through her author metrics: 3 documents, 25 citations and an h-index of 2. Among her awards and honors, she was recognized for her publication on Type 2 Diabetes Mellitus and Quality of Life (2022) and received accolades for her leadership roles as Faculty Coordinator and Organizing Committee Member for major scientific events at LPU. Additionally, she serves as a Reviewer for the Population Medicine Journal and engages in academic outreach, environmental awareness, and student development programs. Through her interdisciplinary research and commitment to education, Ms. Priyanka Garg aims to advance pharmacogenomics-based therapeutic strategies and promote evidence-driven healthcare innovation that bridges scientific discovery with societal impact.

Profile: Scopus | ORCID | ResearchGate

Featured Publications

1. Garg, P., & Yanadaiah, P. (2025). Assessment of quality of life among type 2 diabetes mellitus and hypertensive patients in Punjab region: A WHOQoL-BREF based hospital study. Obesity Medicine, 58, 100651.

2. Garg, P., Jallepalli, V. R., & Verma, S. (2024). Unravelling the CXCL12/CXCR4 axis in breast cancer: Insights into metastasis, microenvironment interactions, and therapeutic opportunities. Human Gene, 40, 201272.

3. Garg, P., & Duggal, N. (2022). Type 2 diabetes mellitus, its impact on quality of life and how the disease can be managed–A review. Obesity Medicine, 35, 100459.

 

Paul Padovani | Health and Medicine | Best Researcher Award

Published on by New Scientists

Dr. Paul Padovani | Health and Medicine | Best Researcher Award

Pediatric cardiologist, University Hospital of Nantes, France

Dr. Paul Padovani is a Junior Doctor in Pediatric and Congenital Cardiology (MD, MSc in Clinical Research) at Nantes University Hospital (CHU de Nantes), France, where he integrates clinical practice, research, and digital health innovation to enhance outcomes for children with congenital heart disease. He earned his MD and MSc in Clinical Research, completing specialized cardiovascular medicine training after ranking 372nd in the French National Exam (ECN), with rotations in leading French university hospitals. His research focuses on pediatric and congenital interventional cardiology, quality-of-life assessment and exercise physiology in CHD, simulation-based medical education, and the development of AI/NLP pipelines integrated with OMOP Common Data Model (CDM) to enable structured healthcare data analysis. Professionally, he has contributed to over ten major research projects, including QUALISYSTEMIC, the first nationwide study on systemic right ventricle quality of life, and SIMUL-CHD, a randomized controlled trial on simulation-based communication training, while also leading AI-driven multicenter data initiatives. Dr. Paul Padovani has published 14 peer-reviewed articles, achieving 56 citations and an h-index of 4, reflecting his emerging impact in pediatric cardiology and digital health. He has received competitive research grants and recognition for advancing multicenter clinical studies and digital health programs. He is an active member of the French Society of Pediatric Cardiology (SFCP) and the Association for European Paediatric and Congenital Cardiology (AEPC), participating in international collaborations and peer-reviewed research efforts. His skills encompass clinical trial design, pediatric interventional procedures, simulation-based education, quality-of-life assessments, and AI-enabled data integration. Dr. Paul Padovani’s vision is to bridge clinical innovation, research, and education, improving patient outcomes, fostering reproducible research, and mentoring future leaders. His work is transforming pediatric cardiology, advancing digital health solutions, and establishing him as a globally recognized emerging leader in health and medicine.

Profile: Scopus | ORCID | ResearchGate | Sci Profiles | Scilit | LinkedIn

Featured Publications

1. Padovani, P., Singh, Y., Pass, R. H., Vasile, C. M., Nield, L. E., & Baruteau, A.-E. (2023). E-health: A game changer in fetal and neonatal cardiology? Journal of Clinical Medicine, 12(21), 6865.

2. Vasile, C. M., Padovani, P., Rujinski, S. D., Nicolosu, D., Toma, C., Turcu, A. A., & Cioboata, R. (2023). The increase in childhood obesity and its association with hypertension during pandemics. Journal of Clinical Medicine, 12(18), 5909.

3. Dardari, M., Iorgulescu, C., Bataila, V., Deaconu, A., Cinteza, E., Vatasescu, R., Padovani, P., Vasile, C. M., & Dorobantu, M. (2023). Transvenous lead extraction in a European low-volume center without on-site surgical support. Reports, 6(3), 41.

4. Dardari, M., Cinteza, E., Vasile, C. M., Padovani, P., & Vatasescu, R. (2023). Infective endocarditis among pediatric patients with prosthetic valves and cardiac devices: A review and update of recent emerging diagnostic and management strategies. Journal of Clinical Medicine, 12(15), 4941.

5. Padovani, P., Grunenwald Gronier, C., & Baruteau, A.-E. (2023). Midline crossing right pulmonary veins with dual drainage to the left atrium. Cardiology in the Young, 33(2), 305–308.

 

Yiling Hou | Health and Medicine | Best Researcher Award

Published on by New Scientists

Prof. Dr. Yiling Hou | Health and Medicine | Best Researcher Award

Professor, China West Normal University, China

Prof. Dr. Yiling Hou is a distinguished scientist and Professor at the College of Life Sciences, China West Normal University, recognized as a reserve candidate for academic and technological leadership in Sichuan Province and an overseas high-level talent. She earned her Bachelor of Science in Pharmacy (2005) and Master of Science in Medicinal Chemistry (2008) from Sichuan University, followed by a Doctor of Science in Biochemistry and Molecular Biology (2011) from Sichuan Agricultural University and further enhanced her expertise as a visiting scholar at the Perelman School of Medicine, University of Pennsylvania (2017–2018). Beginning her career as a Teaching Assistant in 2008, she advanced to Lecturer in 2011, Associate Professor in 2011 and full Professor in 2016, also serving as Program Director for Biotechnology (2013–2020) and currently as Deputy Director of the Sichuan Collaborative Innovation Center for Tissue Repair Materials Engineering Technology. Her research focuses on the isolation, purification, structural identification and biological activity of fungal polysaccharides, alongside tumor cell kinetics, spindle dynamics during mitosis, meiosis and the molecular mechanisms underlying cancer progression. Skilled in structural identification, molecular medicine, apoptosis analysis and advanced biopharmaceutical techniques, she has published 104 Scopus-indexed papers with 787 citations and an h-index of 16, reflecting her growing international impact. Prof. Dr. Yiling Hou is an active Councilor of the Sichuan Provincial Microbiology Society and the Sichuan Provincial Youth Federation, highlighting her commitment to scientific community leadership and youth engagement. Honored as an emerging academic leader in Sichuan Province, she continues to guide students and collaborative projects that bridge traditional pharmacology and modern oncology. With her strong publication record, leadership roles and global collaborations, Prof. Dr. Yiling Hou is poised to make transformative contributions to cancer research and molecular therapeutics, advancing biomedical science and inspiring future generations of researchers.

Profile: Scopus | ResearchGate | Sci Profiles | Scilit

Featured Publications

1. Wang, Y., Lu, R., Ding, X., You, Y., Lin, Y., Hou, Y., & Xia, Y. (2025). Structure identification and in vitro immunomodulatory activities of polysaccharide AHL26-P from Arachis hypogaea (Tianfu 26) leaves. Results in Chemistry, 18, 102724.

2. Sun, Z.-A., Zhao, N., Zheng, L., Pan, F., Ding, X., & Hou, Y. (2025, June 26). Comparative studies on the structure and biological activities of two new polysaccharides from Tricholoma flavovirens (TF-P) and Trametes versicolor (TV-P). Results in Chemistry. Advance online publication.

3. Liu, K., Sun, Z., Li, X., Qing, X., Yu, W., Liu, M., Ding, X., & Hou, Y. (2025). Structure characterization and biological activity of polysaccharides from Trametes sanguinea (TS-P) and wild Lentinus edodes (LE-P). Food Bioscience, 68, 106656.

4. Zhou, L., Ding, X., & Hou, Y. (2024). The structure characterization and biological activities of new polysaccharides from Armillariella tabescens (AT-P) and Tricholoma portentosum (TP-P). Results in Chemistry, 18, 4620–4633.

5. Yu, W., Yuan, R., Liu, M., Liu, K., Ding, X., & Hou, Y. (2024). Effects of rpl1001 gene deletion on cell division of fission yeast and its molecular mechanism. Current Issues in Molecular Biology, 46(3), 2576–2597.

 

Cheikh Sokhna | Health and Medicine | Best Researcher Award

Published on by New Scientists

Prof. Cheikh Sokhna | Health and Medicine | Best Researcher Award

Research Director, Institute of Research for Development (IRD), France

Prof. Cheikh Sokhna is a distinguished medical biologist, malariologist and epidemiologist, serving as Research Director at the Institute of Research for Development (IRD), France, director of the Joint Research Team on Infectious, Neglected and Emerging Diseases in the South (MINES) and Team Leader at the Mediterranean Infection University Hospital Institute in Marseille. He holds a Ph.D. in Biomedical Sciences from Cheikh Anta Diop University of Dakar (UCAD, Senegal) and a Habilitation to Direct Research (HDR) in Infectious and Tropical Diseases from Aix-Marseille University (AMU, France). Over the past 25 years, he has focused on malaria, persistent and emerging infectious diseases in West Africa, leading numerous projects and international collaborations with CNRS, Institut Pasteur and the London School of Hygiene and Tropical Medicine. His professional experience includes leadership roles at Aix-Marseille University, IRD, Institut de Microbiologie de la Méditerranée (CNRS) and multiple Pasteur Network centers, reflecting a strong global research presence. Prof. Cheikh Sokhna has supervised 39 theses, including 13 co-supervised between UCAD and AMU and has produced over 480 indexed articles, 2 book directions, and 13 book chapters, with 336 documented publications, 9,382 citations and an h-index of 48. His research interests include infectious diseases, malaria epidemiology, emerging pathogens and tropical disease control and his skills encompass infectious disease research, international development and large-scale scientific project management. He is the first elected President of the Senegalese Society of Parasitology, Mycology and Entomology (SOSEPAME) and actively promotes public science education through media engagements. Prof. Cheikh Sokhna is highly deserving of recognition for his groundbreaking contributions to infectious disease research, mentorship and global health collaborations, demonstrating strong potential to advance high-impact research, strengthen international partnerships and shape the next generation of biomedical scientists.

Profile: Scopus | ORCID | Google Scholar | ResearchGate | Sci Profiles | LinkedIn | ScholarGPS | AD Scientific Index

Featured Publications

1. Lagier, J. C., Khelaifia, S., Alou, M. T., Ndongo, S., Dione, N., Hugon, P., Caputo, A., … Raoult, D…etc (2016). Culture of previously uncultured members of the human gut microbiota by culturomics. Nature Microbiology, 1(12), 1045.

2. Trape, J. F., Tall, A., Diagne, N., Ndiath, O., Ly, A. B., Faye, J., Dieye-Ba, F., … Rogier, C…etc (2011). Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: A longitudinal study. The Lancet Infectious Diseases, 11(12), 925–932.

3. Senghor, B., Sokhna, C., Ruimy, R., & Lagier, J. C. (2018). Gut microbiota diversity according to dietary habits and geographical provenance. Human Microbiome Journal, 7, 1–9.

4. Sougoufara, S., Diédhiou, S. M., Doucouré, S., Diagne, N., Sembène, P. M., & Sokhna, C…etc (2014). Biting by Anopheles funestus in broad daylight after use of long-lasting insecticidal nets: A new challenge to malaria elimination. Malaria Journal, 13(1), 125.

5. Mediannikov, O., Fenollar, F., Socolovschi, C., Diatta, G., Bassene, H., Molez, J. F., … Raoult, D…etc (2010). Coxiella burnetii in humans and ticks in rural Senegal. PLoS Neglected Tropical Diseases, 4(4), e654.

 

Xiaofeng Dai | Medicine Advances | Best Researcher Award

Published on by New Scientists

Prof. Xiaofeng Dai | Medicine Advances | Best Researcher Award

Professor at The First Affiliated Hospital of Xi’an Jiaotong University, China.

Prof. Dr. Xiaofeng Dai is a distinguished expert in precision oncology and plasma medicine, currently serving as Professor and Research Theme Leader at the First Affiliated Hospital of Xi’an Jiaotong University. With dual PhDs in Systems Biology (Genetics) and Econo-Informatics from Finland, she integrates interdisciplinary knowledge across molecular oncology, bioinformatics, and translational medicine. Prof. Dai has established herself as a global leader in exploring the molecular and clinical applications of cold atmospheric plasma (CAP) therapy, publishing over 114 SCI-indexed articles with a cumulative impact factor of 806.74. She is the first or corresponding author of all these works, including four ESI highly cited papers. Her scientific achievements are further marked by 2 U.S. patents, 4 Chinese invention patents, and 10 software copyrights. She has secured and led national and industrial research funding exceeding 10 million RMB. Recognized for her pioneering work, Prof. Dai has received prestigious honors including Academician of the European Academy of Natural Sciences (2023), Outstanding Engineer Award (2022), and selection in the Jiangsu Province 333 High-level Talents Program (2024). As an active contributor to academic societies and a passionate educator, she is committed to translating advanced research into tangible clinical innovations.

Publication Profile

Scopus

Educational Details

  • Ph.D. in Econo-informatics, Aalto University, Finland (2016)

  • Ph.D. in Systems Biology – Genetics, Tampere University of Technology, Finland (2010)

  • M.Sc. in Bioinformatics, University of Tampere, Finland (2010)

  • M.Sc. in Molecular Biology, Chinese Academy of Agricultural Sciences, China (2006)

  • B.Sc. in Biotechnology, Central South University of Forestry and Technology, China (2003)

Professional Experience

  • 2023/06 – Present: Professor, Theme Leader – Precision Oncology, The First Affiliated Hospital of Xi’an Jiaotong University

  • 2017/06 – 2023/05: Professor, Theme Leader – Precision Medicine, Jiangnan University

  • 2014/02 – 2017/05: Associate Professor, Precision Medicine, Jiangnan University

  • 2016/12 – 2017/02: Visiting Scholar, Queensland University of Technology (QUT), Australia

  • 2013/10 – 2014/01: Principal Investigator, Chinese National Human Genome Center

  • 2011/02 – 2013/09: Senior Research Fellow, Helsinki University Central Hospital, Finland

  • 2010/02 – 2011/01: Senior Research Fellow, Institute for Molecular Medicine Finland

  • 2007/03 – 2011/01: Research Fellow, Tampere University of Technology, Finland

Research Interest

Prof. Dai’s research centers on cold atmospheric plasma (CAP)-based therapies in oncology and beyond. Her interests lie in exploring the molecular underpinnings of CAP’s selective cytotoxicity against malignant cells, investigating its influence on cancer stemness, metastasis, and tumor microenvironment. Expanding from cancer, her current work includes the use of CAP in immunomodulation, metabolic disorders, viral prevention, and vaccine enhancement. She also focuses on developing innovative CAP delivery systems such as ingestible CAP capsules and CAP-mediated photodynamic therapy, aiming to enhance its versatility and applicability. Prof. Dai is also addressing key translational barriers—such as CAP’s short-lived reactive components—by designing storage-stable and sustained-release solutions. Her research integrates bioinformatics, molecular biology, and plasma physics to decipher therapeutic pathways and identify CAP-mimicking biomolecules. Through computational modeling and synthetic chemistry, she is developing molecules with CAP-like efficacy, pushing forward the concept of molecular plasma medicine. Her goal is to create clinically adaptable, precision-targeted, and minimally invasive treatment solutions across a wide spectrum of diseases.

Research Skills

Prof. Dai is proficient in a broad array of interdisciplinary research techniques, spanning molecular biology, plasma physics, bioinformatics, and translational medicine. Her core expertise includes the design and execution of high-throughput omics experiments, real-time plasma-matter interaction studies, and in vitro/in vivo cancer models. She is skilled in CRISPR-based functional genomics, computational modeling of plasma-induced cellular responses, and RNA-seq data interpretation. Her strong background in systems biology enables her to construct multi-scale models that integrate molecular, cellular, and clinical data. She has extensive experience in developing biomedical devices and software tools tailored to plasma applications, backed by 10 software copyrights. Her ability to secure industrial partnerships and government funding demonstrates her leadership in translational research. Additionally, Prof. Dai has led cross-disciplinary teams to develop CAP-based interventions for autoimmune diseases, metabolic disorders, and infectious disease prevention. She is also adept at scientific communication, grant writing, project management, and mentoring junior researchers and students.

Awards and Honors

Prof. Dai’s research excellence and leadership have been widely recognized. In 2024, she was named a Level 3 recipient in the prestigious “333 High-Level Talent Program” of Jiangsu Province. In 2023, she was elected an Academician of the European Academy of Natural Sciences, highlighting her international stature. Her innovative research earned her the Outstanding Engineer Young Award in 2022 from the International Scientific Exchange Foundation of China. Earlier honors include being a member of the Dual Innovative Team of Jiangsu Province (2017), receiving the Six Talent Peaks Award (2016), and being named a Leading Talent for Social Undertakings in Wuxi (2015). These accolades underscore her sustained contributions to scientific innovation, particularly in the interdisciplinary domains of bioengineering, oncology, and plasma medicine. They also reflect recognition by both national and international academic bodies, industry collaborators, and government agencies. Her ability to integrate science, education, and clinical translation has made her a respected figure in China’s high-impact research ecosystem.

Author Metrics

  • Total Citations: 4,522

  • Citations by Documents: 4,063

  • Total Publications (Documents): 125

  • h-index: 29

Top Noted Publication

1. Advanced Science (2020)

Title: Innovative precision gene-editing tools in personalized cancer medicine
Journal: Advanced Science

  • IF (2023): ~17.5

  • JCR Rank: Q1 (Multidisciplinary Sciences)

  • Reason: Highly impactful, interdisciplinary, cutting-edge gene-editing research published in a top-tier journal.

2. Trends in Biotechnology (2018)

Title: The emerging role of gas plasma in oncotherapy
Journal: Trends in Biotechnology

  • IF (2023): ~20.0

  • JCR Rank: Q1 (Biotechnology & Applied Microbiology)

  • Reason: Published in a Cell Press journal, which is highly selective. Recognized for trend-setting reviews.

3. Signal Transduction and Targeted Therapy (2025)

Title: Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics
Journal: Signal Transduction and Targeted Therapy

  • IF (2023): ~39.3

  • JCR Rank: Q1 (Immunology/Oncology)

  • Reason: Nature Publishing Group journal with very high impact. Although recent, its publication in a Nature journal signifies top-tier status.

4. Trends in Genetics (2022)

Title: Histone lactylation: epigenetic mark of glycolytic switch
Journal: Trends in Genetics

  • IF (2023): ~12.0

  • JCR Rank: Q1 (Genetics & Heredity)

  • Reason: Cell Press review journal with major influence in the field of epigenetics and gene regulation.

5. Biotechnology Advances (2019)

Title: Standardizing CAR-T therapy: getting it scaled up
Journal: Biotechnology Advances

  • IF (2023): ~14.2

  • JCR Rank: Q1 (Biotechnology)

  • Reason: Authoritative journal in biotechnology with strong clinical and commercial relevance, especially in CAR-T research.

Conclusion

Prof. Dr. Xiaofeng Dai is a leading interdisciplinary scientist advancing cold atmospheric plasma (CAP) therapy in precision oncology and regenerative medicine. With dual Ph.D. degrees, over 100 SCI-indexed publications, and multiple patents, she bridges molecular research with clinical application. Her leadership in securing major research funding and fostering industry collaboration highlights her impact across science and innovation. As an educator and mentor, she is shaping future experts in cancer biology and bioinformatics. Through national and international partnerships, Prof. Dai remains at the forefront of translating high-impact research into real-world medical solutions.